Hyperuricemia
Conditions
Interventions
Monopotassium Citrate 4.53g per day
Tripotassium Citrate monohydrate 6.53g per day
no citrate administration
Sponsors
Dept. of Clinical Pharmacology and Therapeutics, Oita University Faculty of Medicine
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) A healthy subject who is able to understand the explanation of study and follow instructions given by investigators 2) A subjects who gives written informed consent before a screening test
Exclusion criteria
Exclusion criteria: 1) A subject with clinical evidence or history of hepatic, renal, gastrointestinal, hematologic or other diseases that affect the result of this study and safety of subjects 2)A subject with history of allergies of citrate 3)A subject who takes drugs 4)A subject who is out of range of clinical acceptability in medical history and physical examination, and laboratory tests
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum urate | — |
Secondary
| Measure | Time frame |
|---|---|
| urine pH urate clearance | — |
Countries
Japan
Contacts
Public ContactTsutomu Kotegawa
Oita University Faculty of Medicine Department of Clinical Pharmacology and Therapeutics
Outcome results
None listed